4.25 tirzepatide Day 4: Zepbound (Tirzepatide – weight loss indication) FDA Approved: November 2023 for weight management Weight Loss: Up to 22.5% in clinical trials Similar to Mounjaro, but marketed specifically for weight management GLP1 receptor mutations in Azithromycin 250 mg Tablets SIZE::Retatrutide 12mg

4.25 tirzepatide Day 4: Zepbound (Tirzepatide – weight loss indication) FDA Approved: November 2023 for weight management Weight Loss: Up to 22.5% in clinical trials Similar to Mounjaro, but marketed specifically for weight management GLP1 receptor mutations in Azithromycin 250 mg Tablets SIZE::Retatrutide 12mg

GLP1 receptor mutations in humans affect metabolic control and modify the effectiveness of GLP1 receptor-based treatments against type 2 diabetes and obesity | Institut Cochin

FDA-approved drugs are manufactured in ISO Class 5 cleanrooms with validated sterilization processes and undergo sterility testing on every batch

Azithromycin 250 mg Tablets

SIZE::Retatrutide 12mg

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that works by mimicking GLP-1, a naturally occurring hormone, to manage blood sugar levels and promote weight loss through several mechanisms: Delaying gastric emptying to prolong fullness and reduce hunger